GHP Q4 2021

8 GHP / Q4 2021 , As a result, SBAS has launched its research and development of an AI diagnostic test for Covid-19 infected patients that uses only a routine blood test results. Research around the viral infection that has been at the centre of worldwide attention for over a year and a half has found that symptomatic Covid-19 patients develop characteristic changes in their routine blood parameters. However, it is usually only a small fraction of information contained in routine blood test results that is actually extracted. With machine learning, a diagnostic is able to better identify subtle patterns within the data extracted, making it a more ideal tool for recognising the indicators of Covid-19’s presence. Differentiating Covid-19 from 100 other viral and bacterial diseases, based on only 35 routine blood test results, SBAS’s COVID-19 diagnostic model achieves sensitivity of 83.5% and specificity of 99.1% (N=4434). Designed for adults presenting to emergency rooms and hospitals, SBAS’s COVID-19 diagnostic model is fast establishing itself as a highly-valued asset in the global pandemic that continues to dominate headlines over twenty months after it first entered public awareness. Since SBAS Software is made to be used only by physicians, the SBAS team also felt the need to offer something to the end-users. They launched a mobile application for iOS and Android mobile devices called mySmartBlood, which operates by using the SBAS Software model. It is an in vitro diagnostic medical device for symptomatic users that provides a list of potential groups of diseases based solely on users’ blood test results. The users simply download their Mandatory List of Parameters (MBPL), measure the required blood parameters in the nearest laboratory, enter the results in the mySmartBlood application, and create a report. The report can be viewed directly on the phone, or it can be downloaded as a PDF document that users can share with their physician. It’s a great tool that can guide its users to the right healthcare professional, enables physicians to make more accurate diagnostic decisions, and significantly shortens the path to the final diagnosis of the users. Now, SBAS’s research is pushing the abilities of its AI-driven models even further, pursuing the answers to questions such as whether other serious medical conditions like brain tumours could be diagnosed through routine blood tests. Although many within the medical and healthcare sectors still show reluctance to embrace the power of AI in advancing scientific research within this sphere, SBAS is pioneering the move to its acceptance. From demonstrating its algorithm’s alignment to the Seven Principles of Healthcare Ethics – those being autonomy or self-determination, beneficence, nonmaleficence, confidentiality, justice, role fidelity and veracity – to its publication and recognition on internationally acclaimed platforms including the Scientific Reports and the 38th Annual J.P Morgan Healthcare Conference in San Francisco, SBAS is demonstrating its increasing and impressive credibility. Now, in addition to its recent receipt of its CE mark for SBAS Software and mySmartBlood and ISO 13485 standard certificate stating that Smart Blood Analytics Swiss SA meets all EU safety and health requirements and is cleared for entry into the EU and EEA areas, SBAS is celebrating further success. The firm has won the award for Most Innovative Machine Learning Blood Analytics Tool, 2021 at the GHP – Global Excellence Awards, a testament to the advanced and pioneering technology developed by a team with unparalleled expertise and commitment to the progression of medical science. Contact: Ziga Osterc Company: Smart Blood Analytics Swiss SA Web Address : www.smartbloodanalytics.com SBAS Software result presentation for Gastroenterology machine learning model